BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.450
-0.100 (-6.45%)
Dec 30, 2024, 11:15 AM EST - Market open
BioRestorative Therapies Revenue
BioRestorative Therapies had revenue of $233.60K in the quarter ending September 30, 2024, with 660.91% growth. This brings the company's revenue in the last twelve months to $377.00K, up 189.55% year-over-year. In the year 2023, BioRestorative Therapies had annual revenue of $145.80K with 21.70% growth.
Revenue (ttm)
$377.00K
Revenue Growth
+189.55%
P/S Ratio
28.39
Revenue / Employee
$34,273
Employees
11
Market Cap
10.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
Dec 31, 2020 | 77.00K | -53.00K | -40.77% |
Dec 31, 2019 | 130.00K | 19.00K | 17.12% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
BRTX News
- 25 days ago - BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program - GlobeNewsWire
- 6 weeks ago - BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - GlobeNewsWire
- 3 months ago - BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 3 months ago - BioRestorative Therapies' IFATS 2024 Presentation to Feature ThermoStem® Platform's Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs - GlobeNewsWire
- 4 months ago - BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - BioRestorative Therapies' Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine - GlobeNewsWire
- 6 months ago - BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program - GlobeNewsWire